profit from every $100 of sales.
$0$100
Nutriband
We have no price for Nutriband since 30 September 2026. It may have been taken over, merged or renamed, so the figures below are from then.
$0.55-68.21% today
-75.4% in 1 year
1-year low $0.201-year high $2.63
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2023 to 2026.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Nutriband sold, what it kept, and what it did with the cash.
Sales went from $2.08 million in 2023 to $2.04 million in 2026, with -$8.23 million of profit last year.
SalesProfit
Nutriband vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Nutriband | No profit yet | ||
 Vertex Pharmaceuticals | 35.1× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 22.0× · Fair price | ||
 CSL | 22.1× · Fair price |
AI analysis
An AI analyst reads Nutriband's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| 2 | 2 | 2 | 2 | |
| 1 | 1 | 1 | 1 | |
| -4 | -5 | -7 | -8 | |
| -4 | -5 | -10 | -8 | |
| -4 | -5 | -10 | -8 | |
| – | – | – | – | |
| 36.1% | 41.3% | 34.7% | 27.8% | |
| -199.5% | -233.6% | -312.7% | -408.4% | |
| -215.6% | -263.0% | -489.9% | -404.1% |
Balance sheet
| In millions of USD | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Total assets | 9 | 8 | 7 | 8 |
| Cash | 2 | 0 | 4 | 5 |
| Total debt | 0 | 0 | 0 | 0 |
| Total liabilities | 1 | 1 | 1 | 1 |
| 9 | 6 | 6 | 7 | |
| – | – | – | – | |
| -40.4% | -64.0% | -124.9% | -93.6% | |
| -52.3% | -85.2% | -163.1% | -123.2% |
Cash flow
| In millions of USD | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| -3 | -4 | -5 | -5 | |
| 0 | 0 | 0 | 0 | |
| -3 | -4 | -5 | -5 | |
| Dividends paid | – | – | – | – |
| 0 | 0 | 0 | 0 | |
| 1 | 1 | 2 | 3 |
Valuation
- –
- 0.4×
- 0.02
- 6.4×
- 20.9×
- –
- –
- -40.2%
- -19.3%
- 0.0%
Profitability
- 27.8%
- -408.4%
- -404.1%
- -398.9%
- -120.1%
- -97.0%
- -118.3%
- -109.0%
- -123.0%
- 92.9%
Growth
- −0.7%
- –
- −8.8%
- –
- +10.1%
Financial health
- -0.5×
- 0.03
- 2.8%
- -369.1×
- 6.36
- 6.21
- 0.27
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 17%of 889
Bottom 1%of 987
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Apr 29, 2026 | -1.89 | -1.89 | +0.0% |
| Dec 11, 2025 | -0.32 | -2.13 | +84.9% |
| Sep 9, 2025 | -0.18 | -2.12 | +91.6% |
| May 30, 2025 | -0.12 | -0.12 | −4.0% |
| Apr 28, 2025 | -0.50 | -0.50 | +0.4% |
| Dec 4, 2024 | -0.12 | – | – |
| Sep 3, 2024 | -0.15 | – | – |
| May 31, 2024 | -0.21 | – | – |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
29No pass
Benjamin Graham
40No pass
Philip Fisher
24No pass
Peter Lynch
28No pass
Joel Greenblatt
0No pass
Charlie Munger
27No pass
Terry Smith
21No pass
Questions about Nutriband
Is Nutriband a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Nutriband AI analysis
What does Nutriband do?
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. It is in Biotechnology.
Does Nutriband pay a dividend?
No. Nutriband does not pay a dividend at the moment.
How has Nutriband stock done over the past year?
Down 75.4% over the past twelve months, to $0.55. It traded between $0.20 and $2.63 and is 79.1% below its high.
Who are Nutriband's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with Nutriband's.
Prices: daily closes to Sep 30, 2026. Fundamentals: company reports via invest-like data.